Dr. Robert E. Hogan III, MD
Neurology (Epilepsy Physician)
4921 Parkview Pl, Div Neurology Epilepsy, Ste 6c
Saint Louis, MO 63110
- Medicare participating
At a glance
- Medical school
- University of Missouri, Columbia School of Medicine (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 204
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: University of Missouri, Columbia School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Epilepsy Physician primary
MO license 107494 -
Neurology Physician
MO license 107494
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Barnes Jewish Hospital Saint Louis, MO
Medical groups
- Washington University (3,029 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 204
- Services billed
- 328
- Patients’ average age
- 64
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 105 | 91 |
| Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | 96 | 43 |
| Measurement of brain wave activity (eeg), awake and asleep | 60 | 58 |
| Measurement of brain wave activity (eeg), 61-119 minutes | 15 | 15 |
| Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levetiracetam Other prescribers in Saint Louis, MO | 365 |
| Lamotrigine Other prescribers in Saint Louis, MO | 335 |
| Zonisamide Other prescribers in Saint Louis, MO | 126 |
| Divalproex Sodium Er (divalproex sodium) Other prescribers in Saint Louis, MO | 100 |
| Topiramate Other prescribers in Saint Louis, MO | 99 |
| Carbamazepine Er (carbamazepine) Other prescribers in Saint Louis, MO | 95 |
| Clonazepam Other prescribers in Saint Louis, MO | 85 |
| Clobazam | 81 |
| Lacosamide Other prescribers in Saint Louis, MO | 81 |
| Divalproex Sodium Other prescribers in Saint Louis, MO | 74 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 3 payments worth $293 in total to this clinician.
| Neurelis, Inc. | $293 |
|---|
| Travel and Lodging | $160 |
|---|---|
| Food and Beverage | $133 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Neurelis, Inc. Dec 5, 2025 | Travel and Lodging VALTOCO · EPILEPSY · travel to ATLANTA, GA · in-kind | $122 |
| Neurelis, Inc. Dec 5, 2025 | Travel and Lodging VALTOCO · EPILEPSY · travel to ATLANTA, GA · in-kind | $38.40 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 2 companies. The companies reported $173,444 in research payments for these studies, mostly to the institutions running them.
- A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
UCB SA · Enrolling by invitation · NCT05076617 - A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
UCB SA · Recruiting · NCT05077904 - An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
AbbVie Inc. · Terminated · NCT04686786 - A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
AbbVie Inc. · Completed · NCT04244175 - An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.